Real-time bioprint quality control
Your bioprinter is printing blind.
Our system catches failures before they start.
Detects failures in real time.
The problem
Bioprinting fails constantly. Researchers find out too late.
Researchers only detect failures after hours of tedious staining and imaging. Each failure wastes hours of prep, days of diagnosing causes of failure, and hundreds of dollars in cells and reagents.
No reproducibility
Two bioprints made the exact same way can result in very different responses from the exact same drug. The process itself is unreliable.¹
No visibility
Nozzle clogging, shear stress drift, and narrow printability windows cause constructs to fail mid-run with no alert until it's over.²
High stakes, no margin for error
The global bioprinting market is projected to exceed $5.2B by 2030.³ Every failed run burns cells, reagents, and time researchers can't recover.
¹ Grijalva Garces et al., Biofabrication 2024
² Frontiers in Bioengineering & Biotechnology, multiple reviews on extrusion-based failure modes
³ Vantage Market Research. 3D Bioprinting Market Size & Share to Surpass 5.19 Billion USD by 2030. GlobeNewswire, 22 Aug 2023.
The product
The most efficient and reproducible bioprinting process.
If you're testing a drug candidate and need a reliable tissue model (or want to experiment with bioprinting as an evaluation method), we'll bioprint it for you. Every print is monitored in real time. No failed runs you find out about after.
We bioprint it for you
Send us your drug candidate. We handle the entire bioprinting process with full real-time parameter monitoring and guaranteed reproducibility.
Request a pilotAlready have a bioprinter?
Clip our sensor toolhead onto your existing printer in under 15 minutes. Same real-time ML monitoring & corrections to your bioprinting process.
How it works
From unboxing to anomaly detection in three steps.
01
Clip it on
02
Stream every parameter
03
Catch failures in seconds
Who it's for
Built for labs doing serious bioprinting.
Academic core facilities & research labs
High-volume university labs where reproducibility determines publication quality and grant competitiveness. Pilot participants may be eligible to co-apply for SBIR funding.
Biotech startups & pharma R&D teams
Early-stage & established companies using bioprinted tissue models for drug discovery, where failed prints burn runway and delay timelines.
Get in touch
Request a pilot or get in touch.
We're onboarding now. If you want your drug evaluated with 3D vascularization techniques or want to eliminate bioprint failures, let's talk.
Location
San Francisco, CA
Team